Search Results 91-100 of 6283 for Infuse

  1. Clinical trials - Oncology (Medical)

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  2. Study to Assess the Effects of Intravenous Bendavia in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA) - Mayo Clinic

    ... infused 30 minutes before and 3 hours after percutaneous transluminal angioplasty of the renal artery (PTRA). Participation eligibility. Participant ...

  3. Oncology (Medical) - Clinical trials

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  4. What is cancer immunotherapy? - Mayo Clinic News Network

    During this process, the patient receives chemotherapy to prepare to receive the enriched immune cells, which are later infused into their body to target any ...

  5. A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas - Mayo Clinic

    ... infused into their body. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

  6. Clinical trials - Oncology (Medical)

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  7. Oncology (Medical) - Clinical trials

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  8. Clinical trials - Oncology (Medical)

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  9. Clinical trials - Oncology (Medical)

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  10. Clinical trials - Oncology (Medical)

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...